.jpg?format=webp&quality=80&width=3840)
A study introduces a novel Combined Immune Score (CIS)--based model for assessing prognosis in triple-negative breast cancer (TNBC). The research evaluated eight immune markers in 227 TNBC cases, correlating their expression with clinicopathological data and survival outcomes. Positive expressions of PD-1, PD-L1, and OX40L in immune cells were linked to longer progression-free survival, while OX40 in tumor cells was associated with shorter survival. High CIS was linked to significantly better progression-free and overall survival.
Like
Save
Share